{
    "clinical_study": {
        "@rank": "5162", 
        "arm_group": {
            "arm_group_label": "Treatment (tandem transplantation)", 
            "arm_group_type": "Experimental", 
            "description": "See Detailed Description"
        }, 
        "brief_summary": {
            "textblock": "This phase I/II trial is studying how well giving autologous stem cell transplant followed\n      by donor stem cell transplant works in treating patients with relapsed or refractory\n      lymphoma. Peripheral blood stem cell transplant using stem cells from the patient or a donor\n      may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor\n      cells. The donated stem cells may also help destroy any remaining cancer cells\n      (graft-versus-tumor effect)."
        }, 
        "brief_title": "Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma", 
        "condition": [
            "Adult Nasal Type Extranodal NK/T-cell Lymphoma", 
            "Anaplastic Large Cell Lymphoma", 
            "Angioimmunoblastic T-cell Lymphoma", 
            "Childhood Burkitt Lymphoma", 
            "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", 
            "Nodal Marginal Zone B-cell Lymphoma", 
            "Prolymphocytic Leukemia", 
            "Recurrent Adult Burkitt Lymphoma", 
            "Recurrent Adult Diffuse Large Cell Lymphoma", 
            "Recurrent Adult Diffuse Mixed Cell Lymphoma", 
            "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", 
            "Recurrent Adult Grade III Lymphomatoid Granulomatosis", 
            "Recurrent Adult Hodgkin Lymphoma", 
            "Recurrent Adult Immunoblastic Large Cell Lymphoma", 
            "Recurrent Adult Lymphoblastic Lymphoma", 
            "Recurrent Adult T-cell Leukemia/Lymphoma", 
            "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", 
            "Recurrent Childhood Large Cell Lymphoma", 
            "Recurrent Childhood Lymphoblastic Lymphoma", 
            "Recurrent Childhood Small Noncleaved Cell Lymphoma", 
            "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", 
            "Recurrent Grade 1 Follicular Lymphoma", 
            "Recurrent Grade 2 Follicular Lymphoma", 
            "Recurrent Grade 3 Follicular Lymphoma", 
            "Recurrent Mantle Cell Lymphoma", 
            "Recurrent Marginal Zone Lymphoma", 
            "Recurrent Mycosis Fungoides/Sezary Syndrome", 
            "Recurrent Small Lymphocytic Lymphoma", 
            "Recurrent/Refractory Childhood Hodgkin Lymphoma", 
            "Refractory Chronic Lymphocytic Leukemia", 
            "Splenic Marginal Zone Lymphoma", 
            "Waldenstr\u00f6m Macroglobulinemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Burkitt Lymphoma", 
                "Hodgkin Disease", 
                "Immunoblastic Lymphadenopathy", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Leukemia, Prolymphocytic", 
                "Leukemia, T-Cell", 
                "Leukemia-Lymphoma, Adult T-Cell", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphomatoid Granulomatosis", 
                "Waldenstrom Macroglobulinemia", 
                "Mycoses", 
                "Mycosis Fungoides", 
                "Sezary Syndrome", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Large-Cell, Immunoblastic", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Lymphoma, T-Cell", 
                "Lymphoma, T-Cell, Cutaneous", 
                "Lymphoma, Large-Cell, Anaplastic", 
                "Lymphoma, B-Cell, Marginal Zone", 
                "Lymphoma, Extranodal NK-T-Cell", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To evaluate engraftment of human leukocyte antibody (HLA) identical peripheral blood stem\n      cell (PBSC) allografts given after conditioning with total-body irradiation (TBI) (200cGy)\n      +/- fludarabine, 90 mg/m^2 and post-grafting immunosuppression with cyclosporine\n      (CSP)/mycophenolate mofetil (MMF) in refractory or relapsed lymphoma patients following an\n      initial autologous peripheral blood stem cell transplant (PBSCT) for disease cytoreduction.\n\n      II. To determine the non-relapse mortality at day 100 post-non-myeloablative allografting\n      following mobilization and high-dose chemotherapy with autografting.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the disease free survival and overall survival of non-myeloablative\n      allografting following autologous PBSCT.\n\n      OUTLINE:\n\n      CONDITIONING REGIMEN: Patients with matched, related stem cell donors receive\n      cyclophosphamide intravenously (IV) on days -6 and -5 and undergo TBI twice daily (BID) on\n      days -3 to -1. Patients with matched, unrelated stem cell donors receive carmustine IV over\n      3 hours on day -7, etoposide IV over 2 hours BID on days -6 to -3, and cytarabine IV over 3\n      hours BID on days -6 to -3, and melphalan IV over 30 minutes on day -2.\n\n      TRANSPLANTATION: All patients undergo autologous PBSCT on day 0.\n\n      NON-MYELOABLATIVE CONDITIONING: Beginning 40-120 days following PBSC transplant, patients\n      with related donors undergo TBI on day 0. Patients with unrelated donors receive fludarabine\n      IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.\n\n      TRANSPLANTATION: Patients undergo non-myeloablative allogeneic PBSCT on day 0.\n\n      IMMUNOSUPPRESSION: Patients receive cyclosporine orally (PO) BID on days -3 to 56 (patients\n      with related donors) or 100 (patients with unrelated donors) followed by taper to day 180.\n      Patients also receive mycophenolate mofetil PO BID on days 0-27 (patients with related\n      donors) or thrice daily (TID) on days 0-27, then BID on days 28-40 followed by taper to day\n      96 (patients with unrelated donors).\n\n      Some patients may undergo donor lymphocyte infusion if there is evidence of disease\n      progression and no evidence of graft-vs-host disease (GVHD).\n\n      After completion of study treatment, patients are followed up at 1, 1.5, 2, and 3 years and\n      then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with lymphoma (non-Hodgkin lymphoma [NHL], chronic lymphocytic\n             leukemia/small lymphocytic lymphoma [CLL/SLL] or Hodgkin lymphoma) with primary\n             refractory or relapsed disease after standard chemotherapy at high risk of relapse\n             with conventional autografting; patients with a diagnosis of CLL (or small\n             lymphocytic lymphoma) or diagnosis of CLL that progresses to prolymphocytic leukemia\n             (PLL), or T-cell CLL or PLL\n\n          -  Must have an HLA genotypically or phenotypically identical related donor or, at a\n             minimum, a high likelihood of identifying an HLA-matched unrelated donor; the\n             determination of availability of a suitable unrelated donor may be based on a\n             World-Book search\n\n          -  Cross-over to other tandem autologous-allogeneic research protocol (#2241) will be\n             allowed if the patient loses the suitable HLA-matched related or unrelated donor but\n             has an available HLA-haploidentical donor before receiving the allogeneic\n             transplantation and if the patient meets the eligibility criteria of the subsequent\n             study\n\n          -  Cross-over from other tandem autologous-allogeneic research protocol (#2241) will be\n             allowed if a suitable HLA-matched related or unrelated donor is identified before\n             receiving the allogeneic transplantation and if the patient meets the eligibility\n             criteria of the subsequent study\n\n          -  Signed informed consent\n\n          -  Detectable tumor on radiographic studies or bone marrow biopsy prior to mobilization\n             regimen\n\n          -  Expected survival >= 3 months from study entry\n\n          -  DONOR: HLA genotypically or phenotypically identical related donor\n\n          -  DONOR: must consent to granulocyte-colony stimulating factor (G-CSF) (filgrastim)\n             administration and leukapheresis for both PBSC allograft and subsequent donor\n             lymphocyte infusion (DLI)\n\n          -  DONOR: must have adequate veins for leukapheresis or agree to placement of central\n             venous catheter (femoral or subclavian)\n\n          -  DONOR: Age < 75 yrs, older donors may be considered after review at Patient Care\n             Conference\n\n          -  DONOR: Fred Hutchinson Cancer Research Center (FHCRC) matching allowed will be Grades\n             1.0 to 2.1; unrelated donors who are prospectively: Matched for HLA-A, B, C, DRB1 and\n             DQB1 by high resolution typing; only a single allele disparity will be allowed for\n             HLA-A, B, or C as defined by high resolution typing\n\n          -  DONOR: Donors are excluded when preexisting immunoreactivity is identified that would\n             jeopardize donor hematopoietic cell engraftment; this determination is based on the\n             standard practice of the individual institution; the recommended procedure for\n             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel\n             reactive antibody (PRA) screens to class I and class II antigens for all patients\n             before HCT; if the PRA shows > 10% activity, then flow cytometric or B and T cell\n             cytotoxic cross matches should be obtained; the donor should be excluded if any of\n             the cytotoxic cross match assays are positive; for those patients with an HLA Class I\n             allele mismatch, flow cytometric or B and T cell cytotoxic cross matches should be\n             obtained regardless of the PRA results; a positive anti-donor cytotoxic crossmatch is\n             an absolute donor exclusion\n\n          -  DONOR: patient and donor pairs homozygous at a mismatched allele in the graft\n             rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101\n             and the donor is A*0102, and this type of mismatch is not allowed\n\n          -  DONOR: Only G-CSF mobilized peripheral blood mononuclear cells (PBMC) only will be\n             permitted as a hematopoietic stem cell (HSC) source on this protocol\n\n        Exclusion Criteria:\n\n          -  Life expectancy severely limited by disease other than lymphoma\n\n          -  Prior autologous hematopoietic stem cell transplant\n\n          -  Patients at high risk of veno-occlusive disease of the liver (criteria not yet\n             rigorously defined but includes bilirubin > 2.0 mg and serum glutamic oxaloacetic\n             transaminase [SGOT] or serum glutamic pyruvate transaminase [SGPT] > 2 x normal);\n             patients may be accepted outside of this range if cleared by gastrointestinal (GI)\n             consult\n\n          -  Cardiac ejection fraction (EF) < 40% on multi-gated acquisition (MUGA) scan or\n             cardiac echo (or if unable to obtain ejection fraction, shortening fraction of <\n             26%); patients with active or a history of cardiac disease should be evaluated with\n             appropriate cardiac studies and/or consult; ejection fraction is required if age > 50\n             years or there is a history of anthracyclines or history of cardiac disease; patients\n             with a shortening fraction < 26% may be enrolled if approved by a cardiologist\n\n          -  Baseline serum-creatinine > 2.0 mg/dl and a calculated or measured creatinine\n             clearance of < 50 ml/minute\n\n          -  Seropositive for the human immunodeficiency virus (HIV)\n\n          -  Pulmonary dysfunction as measured by a corrected diffusing capacity of the lung for\n             carbon monoxide (DLCO) < 50% of predicted total lung capacity (TLC) < 30%, forced\n             expiratory volume in 1 second (FEV1) < 30% and/or receiving supplementary continuous\n             oxygen; the FHCRC primary investigator (PI) of the study must approve enrollment of\n             all patients with pulmonary nodules\n\n          -  Pregnancy or breast-feeding\n\n          -  Patients with poorly controlled hypertension despite hypertensive medication\n\n          -  Karnofsky score < 60; pediatric criteria: Lansky Play-Performance Score < 40\n\n          -  Patients with cluster of differentiation (CD)34 selected auto grafts\n\n          -  Patients with active non-hematologic malignancies (except nonmelanoma skin cancers);\n             this exclusion does not apply to patients with non-hematologic malignancies that do\n             not require therapy\n\n          -  Patients with a history of non-hematologic malignancies (except nonmelanoma skin\n             cancers) currently in a complete remission, who are less than 5 years from the time\n             of complete remission, and have a > 20% risk of disease recurrence; this exclusion\n             does not apply to patients with non-hematologic malignancies that do not require\n             therapy\n\n          -  DONOR: Identical twin\n\n          -  DONOR: Age less than 12 years\n\n          -  DONOR: Pregnancy\n\n          -  DONOR: Human immunodeficiency virus (HIV) seropositivity\n\n          -  DONOR: Inability to achieve adequate venous access\n\n          -  DONOR: Known allergy to G-CSF\n\n          -  DONOR: Current serious systemic illness\n\n          -  DONOR: Failure to meet FHCRC criteria for stem cell donation\n\n          -  DONOR: Donor (or centers) who will exclusively donate marrow"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 2, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005803", 
            "org_study_id": "1409.00", 
            "secondary_id": [
                "NCI-2010-00130", 
                "1409.00", 
                "P30CA015704", 
                "P01CA078902"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Undergo allogeneic transplantation", 
                "intervention_name": "peripheral blood stem cell transplantation", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "PBPC transplantation", 
                    "PBSC transplantation", 
                    "peripheral blood progenitor cell transplantation", 
                    "transplantation, peripheral blood stem cell"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given IV", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "CPM", 
                    "CTX", 
                    "Cytoxan", 
                    "Endoxan", 
                    "Endoxana"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Undergo radiotherapy", 
                "intervention_name": "total-body irradiation", 
                "intervention_type": "Radiation", 
                "other_name": "TBI"
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given IV", 
                "intervention_name": "carmustine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BCNU", 
                    "BiCNU", 
                    "bis-chloronitrosourea"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given IV", 
                "intervention_name": "etoposide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "EPEG", 
                    "VP-16", 
                    "VP-16-213"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given IV", 
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ARA-C", 
                    "arabinofuranosylcytosine", 
                    "arabinosylcytosine", 
                    "Cytosar-U", 
                    "cytosine arabinoside"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given IV", 
                "intervention_name": "melphalan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Alkeran", 
                    "CB-3025", 
                    "L-PAM", 
                    "L-phenylalanine mustard", 
                    "L-Sarcolysin"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Undergo allogeneic transplantation", 
                "intervention_name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given IV", 
                "intervention_name": "fludarabine phosphate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "2-F-ara-AMP", 
                    "Beneflur", 
                    "Fludara"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given IV", 
                "intervention_name": "mycophenolate mofetil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Cellcept", 
                    "MMF"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Given PO", 
                "intervention_name": "cyclosporine", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ciclosporin", 
                    "cyclosporin", 
                    "cyclosporin A", 
                    "CYSP", 
                    "Sandimmune"
                ]
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "Undergo autologous transplantation", 
                "intervention_name": "autologous hematopoietic stem cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment (tandem transplantation)", 
                "description": "IV donor lymphocyte infusion", 
                "intervention_name": "therapeutic autologous lymphocytes", 
                "intervention_type": "Biological", 
                "other_name": [
                    "AL", 
                    "Autologous Lymphocytes", 
                    "autologous T cells"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Carmustine", 
                "Cyclophosphamide", 
                "Melphalan", 
                "Fludarabine", 
                "Fludarabine monophosphate", 
                "Cytarabine", 
                "Etoposide", 
                "Mycophenolic Acid", 
                "Cyclosporins", 
                "Cyclosporine", 
                "Mycophenolate mofetil", 
                "Vidarabine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 3, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "David G. Maloney", 
                    "phone": "206-667-5616"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }, 
                    "name": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium"
                }, 
                "investigator": {
                    "last_name": "David G. Maloney", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Thomas R. Chauncey", 
                    "phone": "206-762-1010"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "VA Puget Sound Health Care System"
                }, 
                "investigator": {
                    "last_name": "Thomas R. Chauncey", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "D-04103"
                    }, 
                    "name": "Universitaet Leipzig"
                }, 
                "status": "Completed"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Germany"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-Center Trial", 
        "overall_official": {
            "affiliation": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", 
            "last_name": "David Maloney", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The rates and accompanying confidence intervals associated with failure of engraftment at day +56 will be calculated after every 5th patient is enrolled on the study. If the lower limit to the appropriate one-sided 80% confidence interval exceeds 25%, this will be considered sufficient evidence of an excess \"failure\" rate and the study will be stopped. For these purposes, all patients will be evaluated together (patients with chemosensitive and chemoresistant disease).", 
                "measure": "Engraftment of HLA identical PBSC allografts", 
                "safety_issue": "Yes", 
                "time_frame": "Day 56"
            }, 
            {
                "description": "The rates and accompanying confidence intervals associated with transplant-related mortality will be calculated after every 5th patient is enrolled on the study. If the lower limit to the appropriate one-sided 80% confidence interval exceeds 25%, this will be considered sufficient evidence of an excess \"failure\" rate and the study will be stopped. For these purposes, all patients will be evaluated together (patients with chemosensitive and chemoresistant disease).", 
                "measure": "Non-relapse mortality", 
                "safety_issue": "No", 
                "time_frame": "Day 100 post-non-myeloablative allografting following mobilization and high-dose chemotherapy with autografting"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005803"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Though progression-free survival (PFS) and overall survival (OS) will be analyzed for the trial as a whole, chemosensitive and chemoresistant patients will be analyzed separately for PFS and OS for comparison to their respective historical controls. These groups will be looked at separately to gather preliminary data on whether or not there appears to be a difference in the PFS among patients who had chemosensitive vs chemoresistant disease.", 
            "measure": "Disease-free survival and overall survival", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Fred Hutchinson Cancer Research Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Fred Hutchinson Cancer Research Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 1999", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }, 
    "geocoordinates": {
        "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium": "47.606 -122.332", 
        "Universitaet Leipzig": "51.349 12.394", 
        "VA Puget Sound Health Care System": "47.606 -122.332"
    }
}